Arcadia Biosciences (RKDA) Asset Writedowns and Impairment (2019 - 2024)

Arcadia Biosciences (RKDA) has 6 years of Asset Writedowns and Impairment data on file, last reported at $154000.0 in Q3 2024.

• Quarterly Asset Writedowns and Impairment fell 38.89% year-over-year to $154000.0 in Q3 2024, while the trailing twelve-month figure through Dec 2025 was $154000.0 (changed 0.0% YoY) and the FY2025 annual result came in at $4.7 million, up 2981.17% from the prior year.
• Asset Writedowns and Impairment declined to $154000.0 in Q3 2024, from $252000.0 in the prior quarter.
• In the past five years, Asset Writedowns and Impairment ranged from a high of $3.3 million in Q4 2021 to a low of -$3.1 million in Q4 2020.
• A 5-year average of $379000.0 and a median of $231000.0 in 2021 frame the typical range for Asset Writedowns and Impairment.
• Annual changes were most pronounced in 2020 — Asset Writedowns and Impairment sank 1107.57% — and 2023, when it surged 1580.0%.
• Tracing RKDA's Asset Writedowns and Impairment over 5 years: stood at -$3.1 million in 2020, then jumped by 207.74% to $3.3 million in 2021, then plunged by 109.39% to -$310000.0 in 2022, then surged by 181.29% to $252000.0 in 2023, then slumped by 38.89% to $154000.0 in 2024.
• The last three Asset Writedowns and Impairment figures came in at $154000.0 (Q3 2024), $252000.0 (Q3 2023), and $169000.0 (Q2 2023), per Business Quant data.